Neuroprotect Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Disease Research
The site focuses on therapies that modulate the immune system to address neurodegenerative conditions such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Trials aim to assess long‑term safety, immunogenicity, and potential disease‑modifying effects of novel antibodies.
- Long‑term safety monitoring of immune‑targeted biologics
- Immunogenicity profiling and biomarker analysis
- Evaluation of disease progression endpoints
Eight investigators drive these studies, contributing to a growing portfolio of eleven trials at the Warsaw facility.
Musculoskeletal Disease Trials
Research in the musculoskeletal domain includes the investigation of Myasthenia Gravis and muscle‑related spasticity in Multiple Sclerosis. The primary goal is to determine optimal dosing and functional improvement while ensuring patient tolerability.
- Dose‑response assessment in autoimmune muscle weakness
- Spasticity reduction strategies for demyelinating disease
- Functional outcome measurements in clinical settings
The multidisciplinary team collaborates closely with local neurology and rehabilitation units to enhance trial efficiency.
Nervous System Disease Studies
A broad spectrum of trials addresses disorders of the nervous system, including Alzheimer's Disease, Multiple Sclerosis subtypes, Progressive Supranuclear Palsy, Focal Onset Seizures, and Amyotrophic Lateral Sclerosis. Objectives range from testing new disease‑modifying agents to improving symptom management and quality of life.
- Neuroprotective agent efficacy in early Alzheimer’s
- Relapse reduction in relapsing‑remitting Multiple Sclerosis
- Progression slowing in Progressive Supranuclear Palsy
- Seizure frequency control with novel anticonvulsants
- Ventilation‑free survival in ALS
With eleven active studies and a dedicated staff of eight investigators, the Warsaw center positions itself as a hub for innovative neurological research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 88 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 87 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1Novartis Pharma AG4active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG10trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neuroprotect Sp. z o.o.
lock Showing 1 of 60 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 88 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 7 | Unknown | 2019-09-19 | 2026-02-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.